Know Cancer

or
forgot password

Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others


N/A
18 Years
N/A
Open (Enrolling)
Both
Thyroid Cancer, Papillary Microcarcinoma

Thank you

Trial Information

Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others


Inclusion Criteria:



Thyroid cancer patient eligibility will include:

- Thyroid cancer patients who have been diagnosed with papillary microcarcinoma (or
subcentimeter thyroid lesions with fine needle aspiration biopsy suspicious for
papillary or follicular thyroid cancer) within the prior 6-12 months as per EMR path
report and clinician assessment;

- Presented with the option of treating their papillary microcarcinomas with either
surgery or active surveillance as per treating physician;

- English-fluent;

- 18 years of age or older;

Patient-designated significant other eligibility will include:

- Nomination by patient as individual who assisted patient in decision-making regarding
how to treat thyroid papillary microcarcinoma;

- English-fluent;

- 18 years of age or older;

Exclusion Criteria:

Thyroid cancer patient exclusion criteria will include:

- Thyroid cancer patients with known loco-regional or distant metastases prior to
initial surgical intervention as per path report.

Type of Study:

Observational

Study Design:

Observational Model: Family-Based, Time Perspective: Prospective

Outcome Measure:

To explore patients' and families' perceived risks and benefits of active surveillance and surgery within the context of papillary microcarcinoma.

Outcome Description:

We'll conduct focus groups & individual interviews with 2 population segments established by the method of Krueger & Casey & Morgan. The population segments will be thyroid cancer patients who have had surg or have scheduled surg, & any pt-designated significant others who assisted pts with tx decision-making & thyroid cancer pts who chose to not have immediate surg, whether they are either postponing their tx decision until a later date, or have committed to active surveillance rather than surg, & any pt-designated significant others who assisted these patients with tx decision-making.

Outcome Time Frame:

5 years

Safety Issue:

No

Principal Investigator

Carma Bylund-Lincoln, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

11-108

NCT ID:

NCT01392222

Start Date:

June 2011

Completion Date:

June 2016

Related Keywords:

  • Thyroid Cancer
  • Papillary Microcarcinoma
  • focus group
  • 11-108
  • Thyroid Neoplasms

Name

Location

Memorial Sloan Kettering Cancer CenterNew York, New York  10021